Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -171.51% is 108% below its 5-year average of -82.33%, near the low end of its 5-year range (-171.51%–-15.44%).
18.91% below its 12-month average of -144.24%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -58.26%.
RETURN ON ASSETS (ROA)
-171.51%
RETURN ON ASSETS (ROA) AVG TTM
-144.24%
RETURN ON ASSETS (ROA) AVG 3Y
-112.57%
RETURN ON ASSETS (ROA) AVG 5Y
-82.33%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-18.91%
CURRENT VS 3Y AVG
-52.35%
CURRENT VS 5Y AVG
-108.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-511.55%
vs the sector median at left
Clene Inc.
Market Cap
$49.00M
Return on Assets (ROA)
-171.51%
TTM Avg
-144.24%
3Y Avg
-112.57%
5Y Avg
-82.33%
Market Cap
$48.03M
Return on Assets (ROA)
-71.66%
TTM Avg
-64.58%
3Y Avg
-65.51%
5Y Avg
-55.75%
Market Cap
$47.47M
Return on Assets (ROA)
-166.66%
TTM Avg
-126.93%
3Y Avg
-59.31%
5Y Avg
-48.60%
Market Cap
$50.95M
Return on Assets (ROA)
-97.71%
TTM Avg
-228.91%
3Y Avg
-360.64%
5Y Avg
-295.62%
Market Cap
$51.28M
Return on Assets (ROA)
-68.60%
TTM Avg
-124.17%
3Y Avg
-83.59%
5Y Avg
-65.75%
Market Cap
$51.51M
Return on Assets (ROA)
-127.67%
TTM Avg
-99.17%
3Y Avg
-76.90%
5Y Avg
-71.83%
Market Cap
$51.61M
Return on Assets (ROA)
5.76%
TTM Avg
13.86%
3Y Avg
7.25%
5Y Avg
29.75%
Market Cap
$51.72M
Return on Assets (ROA)
-22.27%
TTM Avg
-102.93%
3Y Avg
-118.23%
5Y Avg
-95.88%
Market Cap
$45.60M
Return on Assets (ROA)
-57.95%
TTM Avg
4.78%
3Y Avg
-64.05%
5Y Avg
-66.64%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.00M | -171.51% | -144.24% | -112.57% | -82.33% |
| Celularity Inc. (CELU)vs › | $48.03M | -71.66% | -64.58% | -65.51% | -55.75% |
| Lite Strategy, Inc. (LITS)vs › | $47.47M | -166.66% | -126.93% | -59.31% | -48.60% |
| Envoy Medical, Inc. (COCH)vs › | $50.95M | -97.71% | -228.91% | -360.64% | -295.62% |
| INmune Bio, Inc. (INMB)vs › | $51.28M | -68.60% | -124.17% | -83.59% | -65.75% |
| eXoZymes, Inc. (EXOZ)vs › | $51.51M | -127.67% | -99.17% | -76.90% | -71.83% |
| biote Corp. (BTMD)vs › | $51.61M | 5.76% | 13.86% | 7.25% | 29.75% |
| Microbot Medical Inc. (MBOT)vs › | $51.72M | -22.27% | -102.93% | -118.23% | -95.88% |
| BioStem Technologies, Inc. (BSEM)vs › | $45.60M | -57.95% | 4.78% | -64.05% | -66.64% |
| DarioHealth Corp. (DRIO)vs › | $45.37M | 70.17% | -36.93% | -46.92% | -57.84% |
ROA
-171.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -144.35% |
| 2024-12-31 | -144.13% |
| 2023-12-31 | -94.58% |
| 2022-12-31 | -67.24% |
| 2021-12-31 | -15.44% |
| 2020-12-31 | -28.25% |
| 2019-12-31 | -108.59% |
| 2018-12-31 | -0.59% |
| 2017-12-31 | 0.00% |
